4//SEC Filing
Karlson Elisa A. 4
Accession 0001209499-10-000033
CIK 0000930184other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 9:47 PM ET
Size
12.1 KB
Accession
0001209499-10-000033
Insider Transaction Report
Form 4
Karlson Elisa A.
EVP & Chief Administrative
Transactions
- Award
Long-Term Performance Units (RSUs)
2010-03-03+20,048→ 20,048 total→ Common Stock (20,048 underlying) - Award
Non-Qualified Stock Option (right to buy)
2010-03-03$38.47/sh+55,970$2,153,166→ 55,970 totalExercise: $38.47From: 2012-02-01Exp: 2017-02-01→ Common Stock (55,970 underlying)
Footnotes (4)
- [F1]Each Long-Term Performance Unit represents a contingent right to receive between one and three shares of common stock.
- [F2]The Long-Term Performance Units will vest based on total shareholder return (TSR) between a price of $37.41 starting on February 2, 2011 and the average stock price for the prior 20 trading days as of three measurement dates: 25% would vest on November 1, 2013, 50% on February 1, 2014 and 25% on May 1, 2014. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels.
- [F3]The Long-Term Performance Units will vest based on total shareholder return (TSR) between a price of $37.41 starting on February 2, 2011 and the average stock price for the prior 20 trading days as of three measurement dates: 25% would vest on November 1, 2013, 50% on February 1, 2014 and 25% on May 1, 2014. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels.
- [F4]The Stock Options will vest in four equal annual installments on February 1st of 2012, 2013, 2014 and 2015.
Issuer
VALEANT PHARMACEUTICALS INTERNATIONAL
CIK 0000930184
Entity typeother
Related Parties
1- filerCIK 0001435755
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 9:47 PM ET
- Size
- 12.1 KB